The Enhancing Secondary Prevention in Coronary Artery Disease trial

McAlister, Finlay A.; Fradette, Miriam; Majumdar, Sumit R.; Williams, Randall; Graham, Michelle; McMeekin, James; Ghali, William A.; Tsuyuki, Ross T.; Knudtson, Merril L.; Grimshaw, Jeremy
December 2009
CMAJ: Canadian Medical Association Journal;12/8/2009, Vol. 181 Issue 12, p897
Academic Journal
Background: Proven efficacious therapies are sometimes underused in patients with chronic cardiac conditions, resulting in suboptimal outcomes. We evaluated whether evidence summaries, which were either unsigned or signed by local opinion leaders, improved the quality of secondary prevention care delivered by primary care physicians of patients with coronary artery disease. Methods: We performed a randomized trial, clustered at the level of the primary care physician, with 3 study arms: control, unsigned statements or opinion leader statements. The statements were faxed to primary care physicians of adults with coronary artery disease at the time of elective cardiac catheterization. The primary outcome was improvement in statin management (initiation or dose increase) 6 months after catheterization. Results: We enrolled 480 adults from 252 practices. Although statin use was high at baseline (n = 316 [66%]), most patients were taking a low dose (mean 32% of the guideline-recommended dose), and their low-density lipoprotein (LDL) cholesterol levels were elevated (mean 3.09 mmol/L). Six months after catheterization, statin management had improved in 79 of 157 patients (50%) in the control arm, 85 of 158 (54%) patients in the unsigned statement group (adjusted odds ratio [OR] 1.18, 95% CI 0.71-1.94, p = 0.52) and 99 of 165 (60%) patients in the opinion leader statement group (adjusted OR 1.51, 95% CI 0.94-2.42, p = 0.09). The mean fasting LDL cholesterol levels after 6 months were similar in all 3 study arms: 2.35 (standard deviation [SD] 0.86) mmol/L in the control arm compared with 2.24 (SD 0.73) among those in the opinion leader group (p = 0.48) and 2.19 (SD 0.68) in the unsigned statement group (p = 0.32). Interpretation: Faxed evidence reminders for primary care physicians, even when endorsed by local opinion leaders, were insufficient to optimize the quality of care for adults with coronary artery disease. ClinicalTrials.gov trial register no. NCT00175240.


Related Articles

  • An Examination of the Evidence Supporting the Association of Dietary Cholesterol and Saturated Fats with Serum Cholesterol and Development of Coronary Heart Disease. Volk, Marion G. // Alternative Medicine Review;Sep2007, Vol. 12 Issue 3, p228 

    The "lipid hypothesis" is the basis for much of the contemporary diet advice and drug therapy aimed at preventing coronary heart disease (CHD), and was developed from a sequential association of dietary lipids, cholesterol, and CHD nearly 100 years ago. The lipid hypothesis considers...

  • Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey. Haq, I. U.; Ramsay, L. E.; Wallis, E. J.; Isles, C. G.; Ritchie, L. D.; Jackson, P. R. // Heart;Sep2001, Vol. 86 Issue 3, p289 

    Objective-To determine the proportion of the population, firstly, with cholesterol ⩾ 5.0 mmol/l and, secondly, with any cholesterol concentration, who might benefit from statin treatment for the following: secondary prevention of coronary heart disease (CHD); primary prevention at CHD risk...

  • Statins in hypercholesterolaemia: A dose-specific meta-analysis of lipid changes in randomised, double blind trials. Edwards, Jayne E.; Moore, R. Andrew // BMC Family Practice;2003, Vol. 4, p18 

    Background: Statins alter lipid concentrations. This systematic review determined the efficacy of particular statins, in terms of their ability to alter cholesterol. Review methods: PubMed, the Cochrane Library, references lists of reports, and reviews were searched (September 2001) for...

  • Direct-To-Consumer Television Advertising Exposure, Diagnosis with High Cholesterol, and Statin Use. Niederdeppe, Jeff; Byrne, Sahara; Avery, Rosemary; Cantor, Jonathan // JGIM: Journal of General Internal Medicine;Jul2013, Vol. 28 Issue 7, p886 

    BACKGROUND: While statin drugs are recommended for secondary prevention of coronary heart disease (CHD), there is no medical consensus on whether or not a statin should be added to lifestyle change efforts for primary prevention of CHD. Previous research suggests that exposure to...

  • Miracle or mirage? Learner, Sue // Nursing Standard;8/1/2007, Vol. 21 Issue 47, p18 

    More than two million people in the UK are taking statins to reduce their cholesterol. But some doctors claim that they can cause affective disorders.

  • Lowering cholesterol in patients with coronary artery disease – the use of statins. Bukachi, F.; Rana, B. S.; Henein, M. Y. // Caribbean Health;Jul1999, Vol. 2 Issue 2, p14 

    The article reports on the use of statins in lowering cholesterol in patients with coronary artery diseases. Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase, the enzyme whose action is the step in the cholesterol biosynthetic pathway. Correction of other risk factors...

  • GPs urged to hold back on statins use.  // Pulse;6/18/2008, Vol. 68 Issue 22, p2 

    The article focuses on the warning issued by the British Hypertension Society asking general practitioners to restrict the use of statins. During a meeting of the International Society of Hypertension, president of British Hypertension Society Gordon McInnes said that physicians should follow...

  • Have the benefits of statins been oversold? Cressey, Daniel // Pulse;4/19/2007, Vol. 67 Issue 15, p20 

    The article presents a debate on the therapeutic effect of statins as a justified primary care prevention in Great Britain. This could be accounted to the transforming cardiovascular disease (CVD) care. Experts believed that the updated Joint British Societies guidelines should be used in...

  • Tailored statin regime best for cuttina coronary events.  // Pulse;1/27/2010, Vol. 70 Issue 2, p10 

    The article reports on the U.S. study which found that tailored statin therapy for patients with high coronary artery disease (CAD) risk is effective in preventing coronary events than treating to a cholesterol target.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics